Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 5Unknown 4Recruiting 4Not yet recruiting 4Terminated 2Active not recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 41Thoracic 17Head & Neck 8Lymphoid 4Tumor-Agnostic 3Genitourinary 3Other solid neoplasm 2Gynecologic 2CNS 2Breast 1

Conditions

Recurrence 2Hodgkin Disease 2Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Cyclophosphamide 30Rituximab 23zanubrutinib 18fludarabine 14Vincristine 14venetoclax 13Prednisone 13blinatumomab 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Doxorubicin 11obinutuzumab 10Bendamustine Hydrochloride 10Lenalidomide 9Dexamethasone 8polatuzumab vedotin 7glofitamab 7Methotrexate 7Radiotherapy 6Prednisolone 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Cytarabine 6Biopsy 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × tislelizumab × Lymphoid × Clear all
NCT07502768 2026-03-31

EpiRev-NKT

Fudan University

Phase 1/2 Not yet recruiting
107 enrolled
Lymphoid

Recurrence, Lymphoma, Extranodal NK-T-Cell

NCT07031700 2025-06-22

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
22 enrolled
Lymphoid

Lymphoma, Follicular

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05627115 2023-11-29

RATiFY

University College, London

Phase 2 Not yet recruiting
80 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡